Drug Approval | December 17, 2023
Zydus receives final USFDA approval for Cyclophosphamide Capsules USP, 25 mg and 50 mg
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
Subscribe To Our Newsletter & Stay Updated
